Centessa Pharmaceuticals plc
CNTA
Classement en actions
#2960
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical... Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate potent CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874, is a small molecule pharmacological chaperone in Phase I studies, designed to correct the misfolding of the Z variant of alpha-1-antitrypsin, thus addressing alpha-1-antitrypsin deficiency. Furthermore, MGX292, a recombinant modified BMP9 replacement protein, aims to rectify the deficient BMP9 signaling implicated in Pulmonary Arterial Hypertension. The company is also developing OX2R Agonists, which are selective orexin receptor 2 agonists (available as oral and intranasal formulations) intended to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1 by leveraging structural insights. Beyond these, Centessa is exploring further clinical proof-of-concept compounds. CBS001, an anti-LIGHT antibody, is being investigated for inflammatory and fibrotic diseases due to its preferential binding to the inflammatory membrane form of LIGHT. Lastly, CBS004 is a humanized monoclonal antibody specifically targeting BDCA2, a protein found exclusively on plasmacytoid dendritic cells, with potential utility in conditions such as systemic sclerosis, systemic lupus erythematosus, and other autoimmune disorders. Centessa Pharmaceuticals plc was established in 2020 and is headquartered in Altrincham, United Kingdom.
Prix de l'action
$40.50
Dernière synchronisation: 2026-06-29
Capitalisation boursière
$6.22B
Changement (1 jour)
0.00%
Changement (1 an)
77.71%
Pays
GB
Échange Centessa Pharmaceuticals plc (CNTA)
Catégorie
Healthcare
Bénéfices pour Centessa Pharmaceuticals plc (CNTA)
Bénéfices en Mar 2026 TTM : $-249.37M
Selon les derniers rapports financiers de Centessa Pharmaceuticals plc, les bénéfices actuels de l'entreprise sont de $-249.37M. En 2023, l'entreprise a réalisé un bénéfice de $-176.14M, une augmentation par rapport à celui de 2022 qui était de $-216.95M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Centessa Pharmaceuticals plc de 2019 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $-249.37M | 7.06% |
| 2024 | $-232.91M | 32.23% |
| 2023 | $-176.14M | -18.81% |
| 2022 | $-216.95M | -43.17% |
| 2021 | $-381.79M | 3,480.47% |
| 2020 | $-10.66M | 110.69% |
| 2019 | $-5.06M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $5.27B | -2,215.32% |
US
|
|
| $-3.09B | 1,137.94% |
US
|
|
| $-4.02B | 1,510.56% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -882.24% |
NL
|
